

Novel Perspectives on the Design and Development of a Long-Acting Subcutaneous Raltegravir Injection for Treatment of HIV—In Vitro and In Vivo Evaluation

Heba S. Abd-Ellah ^{1,2}, Ramesh Mudududdla ^{1,*}, Glen P. Carter ³ and Jonathan B. Baell ^{1,4,*}

¹ Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia; hebasaleh.chem@gmail.com

² Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt

³ Microbiology and Immunology Department, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC 3001, Australia; glen.carter@unimelb.edu.au

⁴ School of Pharmaceutical Sciences, Nanjing Tech University, No. 30 South Puzhu Road, Nanjing 211816, China

* Correspondence: ramesh.mudududdla@monash.edu (R.M.); jonathan.baell@njtech.edu.cn or jbaell29@gmail.com (J.B.B.); Tel.: +61470330093 (R.M.); +61402194571 (J.B.B.)

Table of content

	Figures	Pages
NMR spectra of key intermediates 9a-b , 10a-b , 11a , 13a-b , 19a-b , and final probes 14-15 , 20-21	S1-S30	1-16
NMR spectra of intermediates 23 , 24 , side products 22 , 26 and prodrug 25	S31-44	17-23




Figure S1. ¹H NMR of **9a** in CDCl₃.




Figure S2. ¹³C NMR of **9a** in CDCl₃.




Figure S3. ¹H NMR of **9b** in CDCl₃.




Figure S4. ¹³C NMR of **9b** in CDCl₃.




Figure S5. ¹H NMR of **10a** in CDCl₃.




Figure S6. ¹³C NMR of **10a** in CDCl₃.




Figure S7. ¹H NMR of **10b** in CDCl₃.




Figure S8. ¹³C NMR of **10b** in CDCl₃.




Figure S9. ¹H NMR of **11a** in CDCl₃.




Figure S10. ¹³C NMR of **11a** in CDCl₃.






Figure S13. ¹H NMR of **13b** in CDCl₃.




Figure S14. ¹³C NMR of **13b** in CDCl₃.




Figure S15. ¹H NMR of probe **14** in DMSO-d₆.




Figure S16. ¹³C NMR of probe **14** in CDCl₃.




Figure S19. ^{13}C NMR of probe **15** in CDCl_3 .




Figure S20. HRMS of probe **15**.




Figure S21. ¹H NMR of **19a** in MeOD.




Figure S22. ¹³C NMR of **19a** in MeOD.




Figure S23. ¹H NMR of **19b** in MeOD.




Figure S24. ¹³C NMR of **19b** in MeOD.




Figure S25. ¹H NMR of probe **20** in MeOD.




Figure S26. ¹³C NMR of probe **20** in MeOD.




Figure S27. HRMS of probe **20**.




Figure S28. ¹H NMR of probe **21** in MeOD.




Figure S29. ¹³C NMR of probe **21** in MeOD.




Figure S30. HRMS of probe **21**.




Figure S31. ¹H NMR of **22** in CDCl₃.




Figure S32. ¹³C NMR of **22** in CDCl₃.






Figure S35. ^{13}C NMR of **23** in CDCl_3 .




Figure S36. ^1H NMR of **24** in MeOD .




Figure S37. ^{13}C NMR of **24** in MeOD.




Figure S38. ^1H NMR of prodrug **25** in MeOD.




Figure S39. ^{13}C NMR of prodrug **25** in MeOD.




Figure S40. DEPT 135 ^{13}C NMR of prodrug **25** in MeOD.




Figure S41. HRMS of prodrug **25**.




Figure S 42. ¹H NMR of **26** in MeOD.




Figure S43. ¹³C NMR of **26** in MeOD.




Figure S44. HRMS of **26**.